While PD-L1 expression alone is not sufficient to predict response [1343], when used in combination with other factors it may help select CRC patients that will respond best to anti-PD-1/PD-L1 drugs [1104,1344]. The gene discussed is PDCD1; the disease is colorectal carcinoma.